John L. Lamattina - Nov 16, 2021 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Director
Signature
By: Charles S. Berkman For: John L. LaMattina
Stock symbol
LGND
Transactions as of
Nov 16, 2021
Transactions value $
-$626,409
Form type
4
Date filed
11/17/2021, 04:06 PM
Previous filing
Jun 7, 2021
Next filing
Jun 13, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Options Exercise $156K +4.84K +19.04% $32.30 30.2K Nov 16, 2021 Direct
transaction LGND Common Stock Sale -$783K -4.84K -15.99% $161.86 25.4K Nov 16, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LGND Non-Qualified Stock Option (right to buy) Options Exercise $0 -4.84K -100% $0.00* 0 Nov 16, 2021 Common Stock 4.84K $32.30 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.36 to $164.12, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 11, 2013, and fully vested on the first anniversary of the grant date.